INNV trades 41.6% above Wall Street's consensus target of $6.80.
Last 12 months price action with 12-month analyst target path
The base valuation assumes INNV achieves its forward estimates and maintains a stable P/E multiple of 107.8x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, InnovAge Holding Corp. (INNV) has a Wall Street consensus price target of $6.80, based on estimates from 8 covering analysts. With the stock currently trading at $11.65, this represents a potential downside of -41.6%. The company has a market capitalization of $1.58B.
Analyst price targets range from a low of $5.00 to a high of $8.00, representing a 44% spread in expectations. The median target of $8.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, INNV trades at a trailing P/E of -53.0x and forward P/E of 107.8x. Analysts expect EPS to grow +166.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ALHCAlignment Healthcare, Inc. | $4.9B | $24.05 | $24.33 | +1.2% | Buy | 126.2x | 16 |
OSCROscar Health, Inc. | $8.1B | $31.12 | $24.20 | -22.2% | Hold | 29.8x | 11 |
ENSGThe Ensign Group, Inc. | $10.0B | $170.87 | $222.33 | +30.1% | Buy | 22.6x | 13 |
CCRNCross Country Healthcare, Inc. | $427M | $13.22 | $12.50 | -5.4% | Hold | 142.9x | 14 |
UNHUnitedHealth Group Incorporated | $388.9B | $428.19 | $426.75 | -0.3% | Buy | 23.3x | 52 |
HUMHumana Inc. | $47.4B | $394.62 | $298.50 | -24.4% | Hold | 44.6x | 44 |
CVSCVS Health Corporation | $133.1B | $104.33 | $103.64 | -0.7% | Buy | 14.1x | 41 |
CNCCentene Corporation | $32.6B | $66.12 | $59.79 | -9.6% | Buy | 18.9x | 43 |
MOHMolina Healthcare, Inc. | $12.1B | $232.90 | $178.92 | -23.2% | Buy | 45.4x | 38 |
WELLWelltower Inc. | $166.5B | $237.59 | $237.80 | +0.1% | Buy | 82.0x | 35 |
Quick answers to the most common questions about buying INNV stock.
INNV's consensus price target is $6.8, -41.6% below the current price of $11.65. The 8 analysts tracking INNV see downside risk at present valuations.
INNV has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is leaning bearish, with 2 Sell/Strong Sell ratings. The consensus 12-month price target of $6.8 implies -41.6% downside from current levels.
At a forward P/E of 107.7706x, INNV trades at a premium valuation. The consensus price target of $6.8 (-41.6% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $8 for INNV, while the most conservative target is $5. The consensus of $6.8 represents the median expectation. These targets typically reflect 12-month expectations.
INNV is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month INNV stock forecast based on 8 Wall Street analysts shows a consensus price target of $6.8, with estimates ranging from $5 (bear case) to $8 (bull case). The median consensus rating is "Hold".
INNV trades at a forward P/E ratio of 107.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on INNV, with 2 Sell ratings and a price target of $6.8 (-41.6% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
INNV analyst price targets range from $5 to $8, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.8 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.